Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in SARS-CoV-2–related lung injury
IRCT20200314046764N1Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pirfenidone in pulmonary fibrosis (PF), acute respiratory distress syndrome (ARDS) and not applicable; "lung injury" is not a specific disease, sponsored by Kermanshah University of Medical Sciences. Started Apr 2020; status: completed.
02
Drugs
pirfenidone
03
Conditions
pulmonary fibrosis (PF)acute respiratory distress syndrome (ARDS)not applicable; "lung injury" is not a specific disease
Beyond the preview
Go deeper on IRCT20200314046764N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200314046764N1.